Remove FDA Remove Government Remove Networking Remove Pharmaceutical products
article thumbnail

Data integrity considerations in Pharma and Life Sciences

European Pharmaceutical Review

Regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) place great importance on data integrity in the pharmaceutical/life science industry. Blockchain technology creates a decentralised and unalterable ledger that records all transactions across a network of computers.

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

Manufacturing delays and capacity issues that continue to impact the pharmaceutical supply chain have led to medicine shortages around the globe; an issue that has been exacerbated further by geopolitical events, the energy crisis and rising inflation. What are the top three supply-related challenges facing pharmaceutical manufacturers?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Securing every dose with an edible security technology for safe medicines

European Pharmaceutical Review

1 Simply, pharmaceutical products are the most vulnerable to counterfeiting. 2 The global counterfeit pharmaceuticals trade is estimated to be worth billions annually, 3 bolstered significantly by the increased illicit online pharmacies that emerged during the COVID-19 pandemic. This allows for a cyber?physical

article thumbnail

Pharma Marketing: A Guide for Healthcare Companies

Pharma Marketing Network

Pharmaceutical marketing is the process of communicating the benefits of a pharmaceutical product to potential patients and healthcare providers. It can be a complex and challenging process, as pharmaceutical companies must adhere to strict regulations while also developing creative and effective marketing campaigns.

article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

This also occupies a large resource, given the US Food and Drug Administration (FDA) requirement for double plate checking using a second ‘independent’ person. Tony Cundell: Perhaps the second greatest challenge is the ongoing transition from products based on small molecules to large molecules to cellular therapies.

article thumbnail

Uri Goren

Cadensee

40:28 Are there any social networking tools that can be used to differentiate B2B from B2C. But there's a lot of other things that bother patients and might be a target for healthcare technology, or pharmaceutical products. Are there any social networking tools that you can use to do that? It's a different part of it.